{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:15:13Z","timestamp":1783354513348,"version":"3.54.6"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of intravenous (IV) iron in non-dialysis-dependent chronic kidney disease (ND-CKD) without anaemia remains uncertain. Iron deficiency (ID) in CKD is common and associated with impaired mitochondrial function, fatigue, cognitive decline, and restless legs syndrome, even when haemoglobin (Hb) levels are normalized. ID is linked to cardiovascular (CV) outcomes and increased hospitalization risk. Guidelines are inconsistent, and the evidence base is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases were searched for randomized controlled trials (RCTs) and cohort studies involving adults with ND-CKD (estimated glomerular filtration rate [eGFR] &amp;lt; 60) receiving IV iron compared with oral iron, placebo, or no treatment. Primary outcome was change in iron indices. Secondary outcomes: CV events, infections, physical function, symptoms, cognition, and quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies met the inclusion criteria. In pooled analyses restricted to RCTs, IV iron significantly improved TSAT [mean difference (MD) +7.48%, 95% CI 5.64\u20139.32; P\u00a0&amp;lt;\u00a0.001; I\u00b2 = 0.0%] and ferritin (MD +208.83 ng\/ml, 95% CI 128.39\u2013289.26; P\u00a0=\u00a0.004; I\u00b2 = 75.9%). IV iron was associated with a numerically greater increase in Hb, although this did not reach statistical significance (MD +5.33 g\/l, 95% CI \u22121.18 to 11.84; P\u00a0=\u00a0.080; I\u00b2 = 57.4%). No significant effect was observed on 6-minute walk test distance (MD +23.99 m, 95% CI \u221277.44 to 125.41; P\u00a0=\u00a0.506; I\u00b2 = 83.0%). QoL outcomes showed no significant difference in the primary standardized mean difference (SMD) meta-analysis (SMD \u22120.23, 95% CI \u22121.44 to 0.98; P\u00a0=\u00a0.587; I\u00b2 = 83.2%). Adverse events, CV outcomes and infections were sparsely reported, with no consistent safety signal identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IV iron improves biochemical markers of ID in ND-CKD without anaemia, with no clear signal of harm. However, evidence does not demonstrate measurable improvements in physical function or QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag172","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:43:44Z","timestamp":1780746224000},"source":"Crossref","is-referenced-by-count":0,"title":["A systematic review investigating the safety and efficacy of intravenous iron in people with ND-CKD who are iron deficient but not anaemic"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-773X","authenticated-orcid":false,"given":"Sebastian","family":"Spencer","sequence":"first","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust , Hull ,","place":["UK"]},{"name":"Hull York Medical School , Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Northern Care Alliance (NCA), NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maeve","family":"McGing","sequence":"additional","affiliation":[{"name":"Haxby Group Medical Practice , Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-9622","authenticated-orcid":false,"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust , Hull ,","place":["UK"]},{"name":"Hull York Medical School , Hull ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026070611161774600_bib1","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"2026070611161774600_bib2","article-title":"Quality and outcomes framework achievement, prevalence, and exceptions data 2022\u201323","author":"NHS Digital"},{"key":"2026070611161774600_bib3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"Lopez","year":"2016","journal-title":"Lancet"},{"key":"2026070611161774600_bib4","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s11255-022-03166-9","article-title":"The prevalence and potential aetiological factors associated with restless legs syndrome in patients with chronic kidney disease: a cross-sectional study","volume":"54","author":"Brzuszek","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2026070611161774600_bib5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neuro.2021.11.003","article-title":"Mitochondrial iron metabolism and neurodegenerative diseases","volume":"88","author":"Cheng","year":"2022","journal-title":"Neurotoxicology"},{"key":"2026070611161774600_bib6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.52586\/4958","article-title":"Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease","volume":"26","author":"Bhandari","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2026070611161774600_bib7","doi-asserted-by":"publisher","first-page":"sfae433","DOI":"10.1093\/ckj\/sfae433","article-title":"Iron management and exercise training in individuals with chronic kidney disease: lived experiences","volume":"18","author":"Lightfoot","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026070611161774600_bib8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/jcm11010125","article-title":"Iron deficiency in heart failure: mechanisms and pathophysiology","volume":"11","author":"Alnuwaysir","year":"2021","journal-title":"J Clin Med"},{"key":"2026070611161774600_bib9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41430-020-00742-z","article-title":"Iron deficiency, fatigue and muscle strength and function in older hospitalized patients","volume":"75","author":"Neidlein","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"2026070611161774600_bib10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/ejhf.513","article-title":"Iron deficiency and risk of early readmission following a hospitalization for acute heart failure","volume":"18","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026070611161774600_bib11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijcard.2018.03.039","article-title":"Impact of iron deficiency on long-term clinical outcomes of hospitalized patients with heart failure","volume":"261","author":"Nakano","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026070611161774600_bib12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13019-022-01897-5","article-title":"Non-anemic iron deficiency predicts prolonged hospitalisation following surgical aortic valve replacement: a single-centre retrospective study","volume":"17","author":"Frise","year":"2022","journal-title":"J Cardiothorac Surg"},{"key":"2026070611161774600_bib13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2026070611161774600_bib14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s13063-021-05574-1","article-title":"Standardised outcomes in nephrology\u2014chronic kidney disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy","volume":"22","author":"Evangelidis","year":"2021","journal-title":"Trials"},{"key":"2026070611161774600_bib15","article-title":"Chronic kidney disease: assessment and management","author":"National Institute for Health and Care Excellence (NICE)","year":"2021"},{"key":"2026070611161774600_bib16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","article-title":"Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale","volume":"67","author":"Ratcliffe","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026070611161774600_bib17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ndt\/gfg493","article-title":"Association between serum ferritin and measures of inflammation, nutrition, and iron in haemodialysis patients","volume":"19","author":"Kalantar-Zadeh","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2026070611161774600_bib18","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.2215\/CJN.01390406","article-title":"The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?","volume":"1","author":"Kalantar-Zadeh","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070611161774600_bib19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/00365510310003003","article-title":"Serum iron concentration as a tool to measure relative iron absorption from elemental iron powders in man","volume":"63","author":"Hoppe","year":"2003","journal-title":"Scand J Clin Lab Invest"},{"key":"2026070611161774600_bib20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1309\/2YT4-CMP3-KYW7-9RK1","article-title":"Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels","volume":"117","author":"Dale","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"2026070611161774600_bib21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04070.x","article-title":"Circadian variations of transferrin saturation levels in iron-overloaded patients: implications for the screening of C282Y-linked haemochromatosis","volume":"120","author":"Guillygomarc\u2019h","year":"2003","journal-title":"Br J Haematol"},{"key":"2026070611161774600_bib22","doi-asserted-by":"publisher","first-page":"999.e1","DOI":"10.1016\/j.amjmed.2007.02.027","article-title":"Biological variability of transferrin saturation and unsaturated iron-binding capacity","volume":"120","author":"Adams","year":"2007","journal-title":"Am J Med"},{"key":"2026070611161774600_bib23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070611161774600_bib24","article-title":"KDIGO 2025 Anemia in CKD Guideline Available for Public Review. KDIGO Guideline. Belgium Nov 4 2024","author":"Kidney Disease Improving Global Outcomes (KDIGO)"},{"key":"2026070611161774600_bib25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026070611161774600_bib26","doi-asserted-by":"publisher","first-page":"18401","DOI":"10.1038\/s41598-023-44578-6","article-title":"Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD","volume":"13","author":"Kassianides","year":"2023","journal-title":"Sci Rep"},{"key":"2026070611161774600_bib27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/biomedicines13081860","article-title":"Investigating the Impact of Ferric Derisomaltose (FDI) on patient-reported quality-of-life outcome measures in iron-deficient but not anaemic patients with chronic kidney disease","volume":"13","author":"Jafri","year":"2025","journal-title":"Biomedicines"},{"key":"2026070611161774600_bib28","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/jcm15041676","article-title":"Expert perspectives on managing iron deficiency in people with CKD and\/or HF","volume":"15","author":"Bhandari","year":"2026","journal-title":"J Clin Med"},{"key":"2026070611161774600_bib29","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026070611161774600_bib30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026070611161774600_bib31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026070611161774600_bib32","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026070611161774600_bib33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070611161774600_bib34","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026070611161774600_bib35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12882-020-02180-2","article-title":"NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease","volume":"21","author":"Kalra","year":"2020","journal-title":"BMC Nephrol"},{"key":"2026070611161774600_bib36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","article-title":"A multicentre prospective double-blinded randomised controlled trial of intravenous iron (ferric derisomaltose) in iron-deficient but not anaemic patients with chronic kidney disease on functional status","volume":"22","author":"Bhandari","year":"2021","journal-title":"BMC Nephrol"},{"key":"2026070611161774600_bib37","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ekir.2023.05.002","article-title":"A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD","volume":"8","author":"Greenwood","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026070611161774600_bib38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000507872","article-title":"Protocol and baseline data of a multicentre prospective double-blinded randomized study of intravenous iron on functional status in patients with chronic kidney disease","volume":"51","author":"Bhandari","year":"2020","journal-title":"Am J Nephrol"},{"key":"2026070611161774600_bib39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12882-022-02896-3","article-title":"The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial","volume":"23","author":"Greenwood","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026070611161774600_bib40","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026070611161774600_bib41","article-title":"International prospective register of systematic reviews","author":"PROSPERO"},{"key":"2026070611161774600_bib42","article-title":"JBI critical appraisal tools","author":"Joanna Briggs Institute"},{"key":"2026070611161774600_bib43","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026070611161774600_bib44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin\u2014a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070611161774600_bib45","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CIA.S516704","article-title":"Molecular and cellular mechanisms linking chronic kidney disease and sarcopenia in aging: an integrated perspective","volume":"20","author":"Chang","year":"2025","journal-title":"Clin Interv Aging"},{"key":"2026070611161774600_bib46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0874","article-title":"A systematic review investigates the safety and efficacy of intravenous iron dosing in peritoneal dialysis","volume":"86","author":"Spencer","year":"2025","journal-title":"Br J Hosp Med"},{"key":"2026070611161774600_bib47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.amjcard.2021.04.042","article-title":"Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure","volume":"152","author":"Ambrosy","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026070611161774600_bib48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14740338.2021.1853098","article-title":"Improving the safety of intravenous iron treatments for patients with chronic kidney disease","volume":"20","author":"Kassianides","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2026070611161774600_bib49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag172\/68488928\/sfag172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag172\/68488928\/sfag172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag172\/68488928\/sfag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:23:27Z","timestamp":1783351407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag172\/8703830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag172","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,8]]},"article-number":"sfag172"}}